AMNIO-MAXX® Amnion Patches
Amnio-Maxx® Dual Layer Amnion Allograft
Dual-Layer Two layers of amniotic tissue provides 2x the growth factors Easy to Use Thicker graft facilitates handling in robotic and laparoscopic surgical proce-
•
•
Surgical Barrier Designed for scar tissue and in ammation reduction potential 1 Easy Placement Dual layer allows placement of the graft on either side, eliminating orientation restrictions in surgical repair Biomechanical Integrity O ers greater tensile strength, shape manipulation and slower resorption in vivo 2 Chorion Free Immune privileged, reducing the risk of adverse
•
•
•
•
®
Effective 26Jun2024 MM-0003 Rev 2
Tissue Recovery & Processing Amniotic Membranes are donated by healthy, pre-screened, consenting women in the US, and processed in accordance with
POTENTIAL BENEFITS OF AMNIOTIC MEMBRANE GROWTH FACTORS: 3*
Tissue regeneration/remodeling Anti-adhesive/anti-scarring Non-Immunogenic Anti-inflammatory Creates an environment which promotes anti-bacterial healing
TISSUE COLLECTION
Placental tissue is donated from live births in the U.S. without harming the mother or baby
DONOR SCREENING
The placenta contains growth factors and proteins that stimulate the body's own healing mechanism, reducing pain, in ammation, and scar tissue 4
A thorough medical and social history is obtained for each donor to ensure eligibility requirements are met
• • • • • • • • • • •
INFECTIOUS DISEASE TESTING HBsAg HBcAb HCVAb HCV NAT HBV NAT HIV NAT • • • • • • HIV 1/2Ab WNV NAT HTLV I/II Ab • RPR/STS
Platelet Derived Growth Factor (PDGF) A & B Vascular Endothelial Growth Factor (VEGF) Transforming Growth Factor beta (TGF β ) Fibroblast Growth Factor (FGF) Epidermal Growth Factor (EGF) Tissue Inhibitors of Metalloproteinases (TIMPs) Collagen Types I, III, IV, V, VII Laminin Fibronectin Proteoglycans Hyaluronic Acid (HA)
• • •
TISSUE PROCESSING
All tissue undergoes a proprietary cleansing process to remove blood contaminants and reduce bioburden
TISSUE STERILIZATION
Tissue is sterilized for an additional level of safety, achieving a sterility assurance level (SAL) of 10 -6
Ordering Information
1. Sinno, Prakash. Plast Surg Int. 2013:146764. 2. Spoerl, et al. Ophthalmic Res. 2004;36(2):71-7 3. Martin, et al. Encyclopedia of Reproduction, 2018;3:387-398. 4. Mamede, et al. Cell Tissue Res. 2012, 349:447–458. *Based on published studies; not speci c to PalinGen Amniotic Membranes
© Royal Biologics, Inc. All Rights Reserved
Effective 26Jun2024 MM-0003 Rev 2
Page 1 Page 2Made with FlippingBook interactive PDF creator